Published online before print May 22, 2008, doi: 10.1161/CIRCRESAHA.108.172064
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2008 American Heart Association, Inc.
Molecular Medicine |
A Specific CD36-Dependent Signaling Pathway Is Required for Platelet Activation by Oxidized Low-Density Lipoprotein
From the Program in Cell Biology (K.C., M.F., R.L.S.), Case Western Reserve University; and Department of Cell Biology (M.F., W.L., R.L.S.), Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
Correspondence to Roy L. Silverstein, MD, Department of Cell Biology NC10, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195. E-mail silverr2{at}ccf.org
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Platelet hyperactivity associated with hyperlipidemia may contribute to development of a prothrombotic state. We previously showed that oxidized low-density lipoprotein (oxLDL) formed in the setting of hyperlipidemia and atherosclerosis activated platelets in a CD36-dependent manner. We now show that mitogen-activated protein kinase c-Jun N-terminal kinase (JNK)2 and its upstream activator MKK4 were phosphorylated in platelets exposed to oxLDL. Using apoE–/– mice as a model of hyperlipidemia, we showed that JNK was constitutively phosphorylated in platelets in a CD36-dependent manner. Inhibition of src kinase activity reduced JNK phosphorylation by oxLDL. Immunoprecipitations revealed that active phosphorylated forms of src kinases Fyn and Lyn were recruited to CD36 in platelets exposed to oxLDL. Pharmacological inhibition of the mitogen-activated protein kinase JNK or src family kinases abolished platelet activation by oxLDL in vitro. Using a murine carotid artery thrombosis model we demonstrated CD36-dependent phosphorylation of platelet JNK within thrombi. Furthermore, pharmacological inhibition of JNK prolonged thrombosis times in wild-type but not cd36-null mice in vivo. These findings suggest that a specific CD36-dependent signaling pathway is required for platelet activation by oxLDL and may provide insights related to development of novel antiplatelet therapies more relevant to atherothrombosis than to normal hemostasis.
Key Words: CD36 • JNK • thrombosis • hyperlipidemia
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
CD36 is an integral membrane protein expressed on monocytes/macrophages,1 platelets,2 microvascular endothelium,1 fat, and muscle.3,4 Although initially identified as a receptor for thrombospondin-1 and malaria-infected erythrocytes,5,6 it is now known to be a class B scavenger receptor that recognizes several unrelated ligands, including thrombospondin-1 and -2,7,8 oxidized phospholipids expressed on oxidized low-density lipoprotein (oxLDL) and apoptotic cell surfaces,9,10 long chain fatty acids,11 amyloidogenic peptides,12 and specific components of microbial cell walls or cell surfaces.13
CD36 is involved in a variety of biological processes including lipid metabolism, inflammation, atherosclerosis, and angiogenesis, depending on the nature of the ligand to which it is exposed and the cell or tissue type on which it is expressed.14 Although CD36 was first isolated and structurally characterized from platelets,2 its functional role on platelets remains incompletely characterized. OKM5, a monoclonal antibody directed against CD36, was observed many years ago to induce platelet activation and aggregation.15 Although the effect was dependent on expression of Fc receptors, it could be blocked by F(ab')2 fragments of the antibody, suggesting that the CD36 epitope was required and that CD36 may transduce platelet activating signals. Many other CD36 monoclonal antibodies have also been shown to have stimulatory effects on platelets.16 Our group in collaboration with others recently showed that platelets bind oxLDL via CD36 and this interaction leads to platelet activation, contributing to a prothrombotic state in the setting of hyperlipidemia.17 However, the mechanisms by which interactions between CD36 and its ligands activate platelets remain unknown.
It is now well established that despite having very short intracytoplasmic domains, CD36 can serve as a signaling molecule. Antibodies to platelet CD36 were shown to coprecipitate the nonreceptor protein tyrosine kinases Fyn, Lyn, and Yes.18 Studies in other cellular systems have linked the signaling function of CD36 to recruitment/activation of src family kinases and activation of specific mitogen-activated protein (MAP) kinases. For example, on microvascular endothelial cells, thrombospondin-1 induces a CD36-dependent antiangiogenic, proapoptotic signal via activation of Fyn, caspase-3, and p38 MAP kinase.19 On macrophages, exposure to oxLDL leads to recruitment of Lyn and activation of c-Jun N-terminal kinase (JNK)2 in a CD36-dependent manner. Inhibition of JNK resulted in significant reduction in uptake of oxLDL and foam cell formation.20 These studies suggest a context-dependent mechanism for CD36 signaling involving specific src and MAP kinases. In platelet biology, MAP kinases have not been studied in detail, although it has been demonstrated that the P2Y1 ADP receptor activates p38 MAP kinase, and p38-deficient mice have prolonged thrombotic occlusion time in a ferric chloride (FeCl3)-induced thrombosis model.21,22 We, thus, hypothesized that CD36-mediated platelet activation might involve specific members of the src and MAP kinase families.
CD36 recognizes a variety of pathological ligands including oxLDL,23 advanced glycation end products,24,25 apoptotic cells,26,27 and cell-derived microparticles.28 We focused on oxLDL because of its essential role in the pathogenesis of atherosclerosis and the known association of oxidative stress, hyperlipidemia, and a prothrombotic phenotype.17,29,30 In studies outlined here, we identified a CD36-dependent signaling cascade responsible for oxLDL-dependent activation of platelets that includes the src kinases Fyn and Lyn, the upstream MAP kinase kinase (MKK)4, and the MAP kinase JNK2. These data indicate that a CD36-dependent signaling pathway is required for activation of platelets by oxLDL and shed new light on the mechanism of platelet hypersensitivity in the setting of atherosclerosis and/or hyperlipidemia.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
All human studies were carried out in accordance with Cleveland Clinic IRB and with informed consent from each donor. All animal studies were carried out with prior approval by the Cleveland Clinic IACUC, and mice were cared for in a facility fully accredited by AALAC and in accordance with all federal and local regulations.
Native LDL (nLDL) and oxLDL were prepared as described previously.20 Whole blood was collected from healthy human volunteers in 0.109 mol/L sodium citrate (1:9 dilution), and platelets were separated by sedimentation, washed, and resuspended in modified Tyrode’s buffer. CaCl2 and MgCl2 were added immediately before platelets were stimulated with various agonists and the activated platelets were analyzed by flow cytometry. Human or murine platelets were lysed, and 40 to 60 µg of lysate protein was used for immunoblotting analysis of phosphorylated JNK, total JNK, phospho-MKK4, and MKK4. In some studies, precleared lysates containing 500 µg protein were incubated with protein A–agarose beads conjugated to anti-Lyn or anti-CD36 IgG overnight at 4°C. Beads were washed, boiled in 2x SDS-PAGE loading buffer, and bound material was analyzed by immunoblotting.
Blood from wild-type (WT), apoE-null, or apoE/cd36 double-null mice maintained on chow or high-fat diet for 3 months beginning at 6 weeks of age was obtained by cardiac puncture after animals were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg). Platelets in platelet-rich plasma were allowed to adhere to silanized slides (DAKO, Carpinteria, Calif), and then double immunocytofluorescence staining was performed using antibodies to phospho-JNK and CD41. Images were obtained with a laser confocal microscope. In some studies, platelets were lysed and analyzed by immunoblot for JNK activation. Li-Cor Odyssey infrared imaging system was used for signal detection and quantification.
Carotid artery thrombosis was induced in 12-week-old male WT and cd36-null mice by topical application of 12.5% ferric chloride as previously described.17 After the vessel was allowed to become completely occluded, the carotid arteries were removed, sectioned (4 to 6 µm) across the thrombi, and analyzed by immunohistochemistry using an antibody to phospho-JNK. For quantification, images were scored on the basis of staining intensity by a blinded observer (0 indicated negative; 1, weak; 2, moderate; 3, intense).31 In some studies, thrombi were dissected away from the vessel wall and pooled (9 per group), and total protein was extracted for analysis by immunoblot.
To study the effect of JNK in thrombosis in vivo, WT or CD36-null mice were exposed to 11Gy of external beam irradiation from a cesium 137 source to induce thrombocytopenia with platelet counts <5% of normal after 5 days.17 Platelets obtained from syngeneic donor mice were labeled with calcein acetoxymethyl ester (final concentration of 0.5 mg/mL) in the presence or absence of the JNK inhibitor SP6000125 (final concentration of 400 nmol/L for 30 minutes). This dose is the minimum active dose and was chosen to avoid potential off-target effects. A total of 2x109 donor platelets were injected through the jugular vein of thrombocytopenic mice 10 minutes before carotid injury with 12.5% FeCl3 to allow the transfused platelets to reach equilibrium in the circulation. For further details, see the online data supplement, available at http://circres.ahajournal.org.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
oxLDL Induces Phosphorylation of JNK2 and MKK4 in Platelets
Previously, we showed that oxidized LDL formed in the setting of hyperlipidemia and oxidant stress binds platelets and promotes platelet activation via CD36 (also see Figure I in the online data supplement)17; however, the underlying mechanism by which platelet CD36 transduces signals and contributes to platelet activation is unknown. Because CD36 signaling in a variety of cell types involves MAP kinases, and we recently showed that the specific MAP kinase JNK was a key component of a macrophage CD36-initiated signaling cascade induced by oxLDL,20 we investigated whether JNK was involved in platelet CD36 signaling induced by oxLDL. We assessed the phosphorylation state of JNK by immunoblot and found that human platelets exposed to oxLDL (50 µg/mL) but not nLDL, had a 3- to 5-fold increase in phosphorylation of JNK2 and its upstream activator MKK4 (Figure 1A). Phosphorylation was time-dependent (Figure 1B), with detectable levels after 1 minute and reaching maximum by 15 minutes. At these time points, neither nLDL nor buffer alone effected JNK phosphorylation (data not shown). JNK phosphorylation was also concentration-dependent (Figure 1C). Concentrations as low as 5 µg/mL were effective at activating JNK, with a maximal effect seen at 25 µg/mL. Treatment of platelets with an RGDS peptide (1 mmol/L) to block fibrinogen binding, or the ADP scavenger apyrase (0.5 U/mL), did not block JNK activation by oxLDL, indicating that phosphorylation was not dependent on outside-in integrin signals or secreted ADP (Figure 1D).
|
Elevated Levels of Platelet JNK Phosphorylation In Vivo Are Associated With Hyperlipidemia and Are CD36-Dependent
We recently identified specific oxidized phospholipids in oxLDL that serve as high-affinity ligands for CD36.9 These oxidized lipids are present in the plasma of "western diet"–fed mice rendered hyperlipidemic by genetic deletion of apoE and transduce prothrombotic signals in a CD36-dependent manner.17 To characterize these signals, we isolated platelet-rich plasma from WT, apoE–/–, and apoE–/–;cd36–/– mice fed normal chow or high-fat western diets and examined the platelets by immunofluorescence microscopy for the presence of phospho-JNK. As shown in Figure 2A and 2B, there was minimal phospho-JNK2 expression in resting platelets from WT mice fed a chow diet. Platelets from apoE–/– mice on chow diet showed a modest increase in JNK phosphorylation, whereas platelets from apoE–/– mice on the western diet showed a marked increase in phospho-JNK staining (P<0.001 compared with those from either of the chow fed strains). Diet-induced JNK phosphorylation was completely eliminated in apoE–/– mice that were also deficient in CD36. Flow-cytometric analysis of platelets in suspension confirmed that those from apoE–/–;cd36–/– mice on a western diet had significantly lower levels of phospho-JNK than those from apoE–/– mice on a western diet (n=3, P<0.05, data not shown). As additional confirmation, we also examined the level of phospho-JNK by immunoblot (Figure 2C) and found an increase in platelets from apoE–/– mice on a western diet compared with platelets from apoE–/– mice on chow diet. The increase was not seen in platelets from apoE–/–;cd36–/– mice on a western diet. These data demonstrate that the interaction between endogenous oxidized lipid ligands and CD36 triggers a signaling cascade leading to JNK activation in platelets.
|
oxLDL-Induced JNK2 Phosphorylation Is Mediated By src Family Kinases
The mechanism by which oxLDL induces JNK phosphorylation was assessed using a panel of specific pharmacological inhibitors. Pretreatment of platelets with the broad spectrum src kinase inhibitor AG1879 blocked oxLDL induced JNK2 activation, whereas the phosphatidylinositol 3-kinase inhibitor LY294002 and the broadly active PKC inhibitor GO6983 had no effect (Figure 3A). These data suggest that JNK activation is downstream of src family kinases and independent of PI3K or PKC signaling pathways.
|
Ligand-Induced Recruitment of Fyn and Lyn Kinases by Platelet CD36 Is Essential for oxLDL-Induced Signaling Events
Previous studies demonstrated that the specific src family kinases Fyn, Lyn, and Yes were coprecipitated from platelet membrane lysates with anti-CD36 antibodies.18 In addition, Fyn and/or Lyn has been shown to be involved in CD36-initiated signaling, leading to MAP kinase activation in macrophages, microglia, and endothelial cells.19,20,32 These studies suggest that the association between CD36 and Fyn and/or Lyn may have a functional role in CD36-mediated signaling in platelets. To test this hypothesis, we performed immunoprecipitation with anti-CD36 monoclonal antibody FA6 and examined the precipitates for the presence of src kinases and their activation state. The amounts of Fyn and Lyn in CD36 immunoprecipitates were markedly increased on oxLDL treatment (Figure 3B). Src family kinases have 2 tyrosine phosphorylation sites; phosphorylation in the activation loop increases kinase activity, whereas phosphorylation in the C terminus renders the kinases inactive. We used an antibody specific to the phosphotyrosine in the activation loop and found that Fyn and to a lesser extent Lyn recruited to CD36 after oxLDL exposure were in the "active" state (Figure 3B). In contrast, oxLDL did not increase the total amount of active tyrosine phosphorylated Fyn or Lyn in the non–CD36-associated fraction (data not shown). We also performed immunoprecipitation with anti-Lyn antibody and probed the tyrosine phosphorylation state with a phosphotyrosine specific antibody 4G10 and found that there was no significant increase in total Lyn tyrosine phosphorylation after exposure to oxLDL (Figure 3C). In sum, these data suggest that recruitment of activated Fyn and Lyn to CD36 in response to oxLDL is a key step in CD36-mediated signaling leading to JNK2 phosphorylation.
oxLDL-Induced Activation of Platelets In Vitro Is Mediated by JNK and src Family Kinases
We next used pharmacological inhibitors to study the functional role of JNK and src kinases in oxLDL-induced platelet activation, using a flow cytometric–based assay for surface exposure of P-selectin as a marker for platelet activation. We found that specific pharmacological inhibition of JNK by SP600125 markedly reduced platelet activation in response to oxLDL (
40% inhibition) (Figure 4A). The inhibitor had minimal effect on platelet activation by other agonists as exemplified by ADP or TRAP (SFLLRN) (Figure 4B and 4C). We also found that inhibition of src family kinases by AG1879 blocked oxLDL-induced platelet activation (55% inhibition) (Figure 4D). These results show that JNK and src family kinases are required for oxLDL-induced platelet activation and suggest that JNK is specific to oxLDL-initiated platelet signaling.
|
CD36-Dependent Activation of JNK Promotes In Vivo Thrombus Formation
To determine whether JNK signaling occurs during thrombosis in vivo, we performed immunohistochemical analysis of carotid artery thrombi induced in mice by FeCl3 injury using a specific antibody for phospho-JNK. As shown in Figure 5A, phospho-JNK was detected in thrombi from both WT and cd36–/– mice. The staining intensity, however, was significantly lower (P=0.003) in thrombi from cd36–/– mice, suggesting that CD36-mediated JNK signaling occurred during thrombus formation in vivo (Figure 5B). As an alternative approach to quantify phospho-JNK levels, we dissected carotid artery thrombi from WT and cd36–/– mice and examined pooled lysates from 9 thrombi in each group by immunoblot. Thrombi from cd36–/– mice had 16% less phospho-JNK than those from WT mice (supplemental Figure II). These data suggest that CD36 contributed to JNK phosphorylation during thrombus formation in vivo.
|
Platelet JNK Inhibition Prolonged Time to Thrombosis in a CD36-Dependent Manner
To define the functional effect of JNK signaling in thrombosis, we transfused platelets pretreated with the JNK inhibitor SP600125 into mice rendered severely thrombocytopenic by irradiation and then monitored carotid artery thrombus formation in vivo in response to injury with 12.5% FeCl3. As shown in Figure 6, inhibition of platelet JNK significantly prolonged the time to thrombosis in mice transfused with WT platelets (2-sample t test, P=0.01) but had no effect in mice transfused with cd36–/– platelets (2-sample t test, P=0.37). Supplemental Figure III shows representative fluorescence images from these studies. These data strongly suggest that CD36 mediated JNK signaling promotes platelet activation and thrombus formation in vivo.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Earlier studies demonstrated that engagement of platelet CD36 with oxLDL in vitro or with endogenous oxidized phospholipid ligands generated in vivo under hyperlipidemic conditions induced platelet activation,17,33,34 but the mechanisms by which platelet CD36 acts as a modulator of platelet activity have not been defined. The studies reported here identify the MAP kinase JNK2 as a critical mediator of CD36-dependent platelet signaling. Our work also sheds light on the specific mechanisms linking CD36 and JNK. Earlier studies demonstrated that antibodies to platelet CD36 coprecipitated Fyn, Lyn, and Yes, suggesting a physical association with these nonreceptor protein tyrosine kinases.18 Consistent with this work, we showed that pharmacological inhibition of src kinases abolished CD36-dependent JNK2 phosphorylation and subsequent platelet activation (Figures 3A and 4
D). Furthermore, we showed that the active phosphorylated form of Fyn and Lyn were recruited to CD36 on oxLDL treatment (Figure 3B). There was no change in the levels of active Fyn or Lyn in the fractions not associated with CD36 (data not shown). These studies, thus, suggest that CD36 functions to assemble a signaling complex in a ligand-dependent manner.
Using apoE-null mice fed a high-fat western diet as a model of hyperlipidemia and oxidant stress, we showed that the CD36 signaling pathway was activated in vivo, leading to increased basal levels of JNK phosphorylation in resting platelets (Figure 2). With mesenteric and carotid thrombosis models, we previously demonstrated that the time to thrombotic occlusion after induction of injury was significantly shorter in hyperlipidemic apoE-null mice than in WT mice.17 This hyperlipidemia-induced prothrombotic phenotype was rescued by genetic deletion of CD36 in the apoE-null background. We, thus, hypothesized that the increased basal JNK activity contributed to CD36-dependent platelet hyperreactivity associated with hyperlipidemia.26 We also showed with a carotid injury model in chow-fed mice that phosphorylation of platelet JNK during thrombus formation in vivo was, in part, CD36-dependent and that pharmacological inhibition of platelet JNK produced a significant antithrombotic effect, supporting a role for the CD36-JNK signaling axis even under nonhyperlipidemia conditions (Figures 5 and 6). These latter studies suggest that CD36 ligands are generated during arterial injury and are consistent with recent data from our laboratory showing that cd36-null mice are less sensitive to carotid injury (ie, have longer times to thrombosis).28 The nature of the CD36 ligands remains to be defined, although recent studies suggest that endothelial cell–derived microparticles could function in this capacity.28
Our findings are consistent with recent studies from other laboratories showing that MAP kinases, including JNK, have a significant role in platelet biology.35–39 Pharmacological inhibition of JNK in a model of arteriolar and venular thrombosis in mice suggested a role in arteriolar but not venular thrombosis.39 It was recently demonstrated that JNK was activated after thrombin exposure and during collagen-induced platelet aggregation.39,40 In the latter process, ADP release was required for JNK activation, although ADP alone was not sufficient to induce JNK activation. In contrast, we demonstrated that oxLDL-induced JNK activation was not dependent on ADP release (Figure 1D). Integrin outside-in signaling was also not required for JNK activation induced by oxLDL, suggesting oxLDL–platelet interactions directly trigger the signaling cascade. We also showed that although pharmacological inhibition of JNK blocked platelet activation by oxLDL, it did not inhibit ADP- or TRAP-induced activation (Figure 4A through 4C), suggesting that JNK may be specific to CD36 signaling. Our studies (data not shown) and those of others have shown that another member of the MAP kinase family, p38, is phosphorylated in platelets after exposure to oxLDL.33,41,42 Whether p38 and JNK work synergistically or independently in the process of platelet activation by oxLDL remains to be determined. The precise function of JNK in platelet biology also remains to be determined. It is known to be involved in a wide variety of diverse cellular processes through transcription-dependent and transcription-independent mechanisms. Because platelets are anucleate cells, it is unlikely that JNK action would be transcription-dependent. It will be important to define substrates of JNK in platelets to further define its functional role.
Several studies have shown that LDL subjected to various methods of in vitro oxidation, including by exposure to metal ions or hydrochlorous acid, can influence platelet function.41–44 Our data clearly identify a central role for the interaction of CD36 with specific oxidized phospholipids within oxLDL in platelet signaling. CD36-specific ligands are generated when LDL is oxidized in vitro and in vivo and have been shown to accumulate in atherosclerotic plaque and to circulate in the blood of patients with hyperlipidemia and atherosclerosis.29,45,46 oxLDL, however, is a complex particle and can contain a variety of biologically active lipids other than CD36 ligands, including lysophosphatidylcholine, platelet-activating factor, lysophosphatidic acid (LPA), and 9- and 13-HODE.47 The role of these other lipids in JNK activation remains unknown. Others have shown that LPA in oxLDL can induce platelet shape change via a specific G protein–coupled LPA receptor.44,48 The signaling pathways triggered by LPA involve tyrosine phosphorylation of specific proteins including Syk and an increase of cytosolic Ca2+.49,50 It is also possible that LPA or platelet-activating factor receptors may work in a synergic way with CD36 and contribute to JNK activation.
|
Acknowledgments |
|---|
Sources of Funding
This work was supported by NIH grant HL81011 and the National Heart, Lung, and Blood Institute Specialized Center for Clinically Oriented Research (SCCOR) in Thrombosis (to R.L.S. and M.F.) and American Heart Association Predoctoral Fellowship 0715088B (to K.C.).
Disclosures
None.
|
Footnotes |
|---|
Original received January 28, 2008; revision received May 13, 2008; accepted May 14, 2008.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Knowles DM II, Tolidjian B, Marboe C, D'Agati V, Grimes M, Chess L. Monoclonal anti-human monocyte antibodies OKM1 and OKM5 possess distinctive tissue distributions including differential reactivity with vascular endothelium. J Immunol. 1984; 132: 2170–2173.[Medline] [Order article via Infotrieve]
2. Rhinehart-Jones T, Greenwalt DE. A detergent-sensitive 113-kDa conformer/complex of CD36 exists on the platelet surface. Arch Biochem Biophys. 1996; 326: 115–118.[CrossRef][Medline] [Order article via Infotrieve]
3. Abumrad NA, el-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem. 1993; 268: 17665–17668.
4. Van Nieuwenhoven FA, Verstijnen CP, Abumrad NA, Willemsen PH, Van Eys GJ, Van der Vusse GJ, Glatz JF. Putative membrane fatty acid translocase and cytoplasmic fatty acid-binding protein are co-expressed in rat heart and skeletal muscles. Biochem Biophys Res Commun. 1995; 207: 747–752.[CrossRef][Medline] [Order article via Infotrieve]
5. Silverstein RL, Asch AS, Nachman RL. Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest. 1989; 84: 546–552.[Medline] [Order article via Infotrieve]
6. Oquendo P, Hundt E, Lawler J, Seed B. CD36 directly mediates cytoadherence of plasmodium falciparum parasitized erythrocytes. Cell. 1989; 58: 95–101.[CrossRef][Medline] [Order article via Infotrieve]
7. Silverstein RL, Nachman RL. Thrombospondin binds to monocytes-macrophages and mediates platelet-monocyte adhesion. J Clin Invest. 1987; 79: 867–874.[Medline] [Order article via Infotrieve]
8. Simantov R, Febbraio M, Silverstein RL. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol. 2005; 24: 27–34.[Medline] [Order article via Infotrieve]
9. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Gugiu B, Fox PL, Hoff HF, Salomon RG, Hazen SL. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem. 2002; 277: 38503–38516.
10. Greenberg ME, Sun M, Zhang R, Febbraio M, Silverstein R, Hazen SL. Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J Exp Med. 2006; 203: 2613–2625.
11. Ibrahimi A, Bonen A, Blinn WD, Hajri T, Li X, Zhong K, Cameron R, Abumrad NA. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem. 1999; 274: 26761–26766.
12. Medeiros LA, Khan T, El Khoury JB, Pham CL, Hatters DM, Howlett GJ, Lopez R, O'Brien KD, Moore KJ. Fibrillar amyloid protein present in atheroma activates CD36 signal transduction. J Biol Chem. 2004; 279: 10643–10648.
13. Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, Sovath S, Shamel L, Hartung T, Zahringer U, Beutler B. CD36 is a sensor of diacylglycerides. Nature. 2005; 433: 523–527.[CrossRef][Medline] [Order article via Infotrieve]
14. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001; 108: 785–791.[CrossRef][Medline] [Order article via Infotrieve]
15. Aiken ML, Ginsberg MH, Byers-Ward V, Plow EF. Effects of OKM5, a monoclonal antibody to glycoprotein IV, on platelet aggregation and thrombospondin surface expression. Blood. 1990; 76: 2501–2509.
16. Silverstein RL, LaSala J, Pearce SF. CD36 cluster report. In: Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Silverstein RL, Springer TA, Tedder TF, Todd RF, eds. Leucocyte Typing V: White Cell Differentiation Antigens. Vol 2. Oxford, England: Oxford University Press; 1995: 1269–1289.
17. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, Hazen SL. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007; 13: 1086–1095.[CrossRef][Medline] [Order article via Infotrieve]
18. Huang MM, Bolen JB, Barnwell JW, Shattil SJ, Brugge JS. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc Natl Acad Sci U S A. 1991; 88: 7844–7848.
19. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000; 6: 41–48.[CrossRef][Medline] [Order article via Infotrieve]
20. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab. 2006; 4: 211–221.[CrossRef][Medline] [Order article via Infotrieve]
21. Dangelmaier C, Jin J, Daniel JL, Smith JB, Kunapuli SP. The P2Y1 receptor mediates ADP-induced p38 kinase-activating factor generation in human platelets. Eur J Biochem. 2000; 267: 2283–2289.[Medline] [Order article via Infotrieve]
22. Sakurai K, Matsuo Y, Sudo T, Takuwa Y, Kimura S, Kasuya Y. Role of p38 mitogen-activated protein kinase in thrombus formation. J Recept Signal Transduct Res. 2004; 24: 283–296.[CrossRef][Medline] [Order article via Infotrieve]
23. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993; 268: 11811–11816.
24. Kuniyasu A, Ohgami N, Hayashi S, Miyazaki A, Horiuchi S, Nakayama H. CD36-mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3–L1 and human subcutaneous adipocytes. FEBS Lett. 2003; 537: 85–90.[CrossRef][Medline] [Order article via Infotrieve]
25. Ohgami N, Nagai R, Ikemoto M, Arai H, Miyazaki A, Hakamata H, Horiuchi S, Nakayama H. CD36, serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complications. 2002; 16: 56–59.[CrossRef][Medline] [Order article via Infotrieve]
26. Platt N, da Silva RP, Gordon S. Recognizing death: the phagocytosis of apoptotic cells. Trends Cell Biol. 1998; 8: 365–372.[CrossRef][Medline] [Order article via Infotrieve]
27. Savill J, Hogg N, Ren Y, Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest. 1992; 90: 1513–1522.[Medline] [Order article via Infotrieve]
28. Ghosh A, Li W, Febbraio M, Espinola RG, McCrae KR, Cockrell E, Silverstein RL. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest. 2008; 118: 1934–1943.[Medline] [Order article via Infotrieve]
29. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991; 88: 1785–1792.[Medline] [Order article via Infotrieve]
30. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2000; 20: 1831–1834.
31. Erden O, Imir A, Guvenal T, Muslehiddinoglu A, Arici S, Cetin M, Cetin A. Investigation of the effects of heparin and low molecular weight heparin on E-cadherin and laminin expression in rat pregnancy by immunohistochemistry. Hum Reprod. 2006; 21: 3014–3018.
32. Moore KJ, El Khoury J, Medeiros LA, Terada K, Geula C, Luster AD, Freeman MW. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem. 2002; 277: 47373–47379.
33. Korporaal SJ, Van Eck M, Adelmeijer J, Ijsseldijk M, Out R, Lisman T, Lenting PJ, Van Berkel TJ, Akkerman JW. Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler Thromb Vasc Biol. 2007; 27: 2476–2483.
34. Volf I, Moeslinger T, Cooper J, Schmid W, Koller E. Human platelets exclusively bind oxidized low density lipoprotein showing no specificity for acetylated low density lipoprotein. FEBS Lett. 1999; 449: 141–145.[CrossRef][Medline] [Order article via Infotrieve]
35. Li Z, Zhang G, Feil R, Han J, Du X. Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of the platelet integrin alphaIIb beta3. Blood. 2006; 107: 965–972.
36. Mazharian A, Roger S, Berrou E, Adam F, Kauskot A, Nurden P, Jandrot-Perrus M, Bryckaert M. Protease-activating receptor-4 induces full platelet spreading on a fibrinogen matrix: involvement of ERK2 and p38 and Ca2+ mobilization. J Biol Chem. 2007; 282: 5478–5487.
37. Song S, Freedman J, Mody M, Lazarus AH. Porcine von Willebrand factor and thrombin induce the activation of c-Jun amino-terminal kinase (JNK/SAPK) whereas only thrombin induces activation of extracellular signal-related kinase 2 (ERK2) in human platelets. Br J Haematol. 2000; 109: 851–856.[CrossRef][Medline] [Order article via Infotrieve]
38. Shankar H, Garcia A, Prabhakar J, Kim S, Kunapuli SP. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost. 2006; 4: 638–647.[CrossRef][Medline] [Order article via Infotrieve]
39. Kauskot A, Adam F, Mazharian A, Ajzenberg N, Berrou E, Bonnefoy A, Rosa JP, Hoylaerts MF, Bryckaert M. Involvement of the mitogen-activated protein kinase c-Jun NH2-terminal kinase 1 in thrombus formation. J Biol Chem. 2007; 282: 31990–31999.
40. Bugaud F, Nadal-Wollbold F, Levy-Toledano S, Rosa JP, Bryckaert M. Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. Blood. 1999; 94: 3800–3805.
41. Coleman LG Jr, Polanowska-Grabowska RK, Marcinkiewicz M, Gear AR. LDL oxidized by hypochlorous acid causes irreversible platelet aggregation when combined with low levels of ADP, thrombin, epinephrine, or macrophage-derived chemokine (CCL22). Blood. 2004; 104: 380–389.
42. Korporaal SJ, Gorter G, van Rijn HJ, Akkerman JW. Effect of oxidation on the platelet-activating properties of low-density lipoprotein. Arterioscler Thromb Vasc Biol. 2005; 25: 867–872.
43. Ardlie NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis. 1989; 76: 117–124.[CrossRef][Medline] [Order article via Infotrieve]
44. Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, Corrinth C, Bittman R, Tigyi G, Aepfelbacher M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A. 1999; 96: 6931–6936.
45. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992; 13: 341–390.[CrossRef][Medline] [Order article via Infotrieve]
46. Sevanian A, Bittolo-Bon G, Cazzolato G, Hodis H, Hwang J, Zamburlini A, Maiorino M, Ursini F. LDL- is a lipid hydroperoxide-enriched circulating lipoprotein. J Lipid Res. 1997; 38: 419–428.[Abstract]
47. Siess W. Platelet interaction with bioactive lipids formed by mild oxidation of low-density lipoprotein. Pathophysiol Haemost Thromb. 2006; 35: 292–304.[CrossRef][Medline] [Order article via Infotrieve]
48. Essler M, Retzer M, Bauer M, Zangl KJ, Tigyi G, Siess W. Stimulation of platelets and endothelial cells by mildly oxidized LDL proceeds through activation of lysophosphatidic acid receptors and the Rho/Rho-kinase pathway. Inhibition by lovastatin. Ann N Y Acad Sci. 2000; 905: 282–286.[Medline] [Order article via Infotrieve]
49. Maschberger P, Bauer M, Baumann-Siemons J, Zangl KJ, Negrescu EV, Reininger AJ, Siess W. Mildly oxidized low density lipoprotein rapidly stimulates via activation of the lysophosphatidic acid receptor Src family and Syk tyrosine kinases and Ca2+ influx in human platelets. J Biol Chem. 2000; 275: 19159–19166.
50. Retzer M, Siess W, Essler M. Mildly oxidised low density lipoprotein induces platelet shape change via Rho-kinase-dependent phosphorylation of myosin light chain and moesin. FEBS Lett. 2000; 466: 70–74.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  D. J. Kennedy, S. D. Kuchibhotla, E. Guy, Y. M. Park, G. Nimako, D. Vanegas, R. E. Morton, and M. Febbraio Dietary Cholesterol Plays a Role in CD36-Mediated Atherogenesis in LDLR-Knockout Mice Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1481 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sun, A. Swaim, J. E. Herrera, D. Becker, L. Becker, K. Srivastava, L. E. Thompson, M. R. Shero, A. Perez-Tamayo, B. Suktitipat, et al. Platelet Kainate Receptor Signaling Promotes Thrombosis by Stimulating Cyclooxygenase Activation Circ. Res., September 11, 2009; 105(6): 595 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Harb, K. Bujold, M. Febbraio, M. G. Sirois, H. Ong, and S. Marleau The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation Cardiovasc Res, July 1, 2009; 83(1): 42 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Silverstein and M. Febbraio CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior Sci. Signal., May 26, 2009; 2(72): re3 - re3. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. SILVERSTEIN Inflammation, atherosclerosis, and arterial thrombosis: Role of the scavenger receptor CD36 Cleveland Clinic Journal of Medicine, April 1, 2009; 76(Suppl_2): S27 - S30. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||